Sex difference in the immunogenicity of the quadrivalent Human Papilloma Virus vaccine: Systematic review and meta-analysis
Vaccine, ISSN: 0264-410X, Vol: 39, Issue: 12, Page: 1680-1686
2021
- 11Citations
- 60Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations11
- Citation Indexes11
- 11
- Captures60
- Readers60
- 60
- Mentions1
- Blog Mentions1
- Blog1
Review Description
Immunological differences between males and females in response to viral vaccines are well known. This the first review to examine them for the Human Papilloma Virus. We conducted a systematic review and meta-analysis of the immunogenicity of the Quadrivalent Human Papilloma Virus Vaccine qHPVV. We searched Medline, Embase, and CENTRAL for trials published until September 17, 2019. Inclusion criteria were 3-doses and reporting geometric mean titers (GMTs). We performed random-effects meta-analyses and meta-regression separated by age group and sex. Our search yielded 1809 unique studies. 334 full texts were screened and data from 18 studies were extracted. Females had higher pooled geometric mean titers than males in all age groups. Log transformed GMTs in male children (<16) years were: against HPV6: 6·62 (95% CI 6·29–6·94; I 2 = 86·0%), against HPV11: 7·07 (95% CI 6·90–7·23; I 2 = 63.1%), against HPV16: 8·53 (95% CI 8·28–8·78; I 2 = 73·0%), and against HPV18 7·21 (95% CI 7·08–7·34; I 2 = 26·4%). In females: against HPV6 7·10 (95% CI 6·79–7·41; I 2 = 96·6%), HPV11: 7·32 (95% CI 7·15–7·50; I 2 = 90·6%), HPV16: 8·71 (95% CI 8·52–8·91; I 2 = 90·2%), and HPV18 7·35 (95% CI 7·11–7·58; I 2 = 92·7%). In the meta-regression, the sexual difference was significant for HPV6 (p = 0·022) with a similar tendency for HPV11 (p = 0·066) and HPV18 (p = 0·079). Immunogenicity was significantly higher in children (<16) than in adults (p < 0·001). Females have higher antibody titers against HPV after receiving the qHPVV than do males. The difference is bigger in low-risk HPV strains. Adjusting the doses and schedules for each sex should be explored further.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0264410X21001705; http://dx.doi.org/10.1016/j.vaccine.2021.02.022; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85101312024&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/33637386; https://linkinghub.elsevier.com/retrieve/pii/S0264410X21001705; https://dx.doi.org/10.1016/j.vaccine.2021.02.022
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know